Inventory (Tables)

6 Months Ended

Jun. 30, 2024

Inventory Disclosure [Abstract]

Schedule of Inventory

The Company capitalizes its purchases of saleable inventory of VASCEPA from suppliers that have been qualified by the U.S. FDA and other global regulatory agencies. Inventories as of June 30, 2024 and December 31, 2023 consist of the following:

In thousands	June 30, 2024		December 31, 2023
Raw materials	$	142,594	$	155,128
Work in process		33,670		5,373
Finished goods		134,438		175,730
Total inventory (1)	$	310,702	$	336,231

(1) Total inventory consists of both current inventory and long-term inventory. During the six months ended June 30, 2024, approximately $1.5 million of inventory was expensed through cost of goods sold for product dating inventory. During the three and six months ended June 30, 2023 approximately $1.1 million and $3.4 million, respectively, of finished goods were expensed through cost of goods sold related to unsellable inventory not related to product dating.